The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays

Abstract

B-cell chronic lymphoid leukemia (B-CLL) is a highly heterogeneous human malignancy, presumably reflecting specific molecular alterations in gene expression and protein activity that are thought to underlie the variable disease outcome. Most B-CLL cell samples undergo apoptotic death in response to DNA damage. However, a clinically distinct aggressive subset of B-CLL is completely resistant in vitro to irradiation-induced apoptosis. We therefore addressed 2 series of microarray analyses on 4 sensitive and 3 resistant B-CLL cell samples and compared their gene expression patterns before and after apoptotic stimuli. Data analysis pointed out 16 genes whose expression varied at least 2-fold specifically in resistant cells. We validated these selected genes by real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) on 7 microarray samples and confirmed their altered expression level on 15 additional B-CLL cell samples not included in the microarray analysis. In this manner, in 11 sensitive and 11 resistant B-CLL cell samples tested, 13 genes were found to be specific for all resistant samples: nuclear orphan receptor TR3, major histocompatibility complex (MHC) class II glycoprotein HLA-DQA1, mtmr6, c-myc, c-rel, c-IAP1, mat2A, and fmod were up-regulated, whereas MIP1a/ GOS19-1 homolog, stat1, blk, hsp27, and ech1 were down-regulated. In some cases, the expression profile may be dependent on the status of p53. Some of these genes encode general apoptotic factors but also exhibit lymphoid cell specificities that could potentially be linked to the development of lymphoid malignancies (MIP1␣, blk, TR3, mtmr6). Taken IntroductionB-cell chronic lymphoid leukemia (B-CLL) results in an accumulation of mature CD5 ϩ /CD23 ϩ B cells in peripheral blood, not due to excessive proliferation (at the early stage of disease, cells are mainly arrested in G 0 /G 1 of the cell cycle), but rather to decreased cell mortality resulting from an uncharacterized defect in apoptotic cell death. 1 The most revealing alteration of gene expression that may explain the prolonged survival of malignant B-cells is the overexpression of the bcl-2 gene resulting from its hypomethylation. 2 Although this overexpression as well as deregulated expression of some other bcl-2 family members 1 is consistent with prolonged cell survival, it does not clearly correlate with disease aggressiveness, clinical outcome, or cell sensitivity to apoptosis induced in vitro. Another gene involved in the apoptotic process through its transducing role in the cellular response to DNA damage is ATM, which is deleted or mutated in an aggressive form of B-CLL. [3][4][5] These alterations can lead to dysfunction of p53, whose direct inactivation by mutation is a relatively rare molecular event in B-CLL. 6 Deregulation of p53 can also result from an altered function of the proteasome system, which we observed in all B-CLL samples tested. 7 Together, these observations make deregulated control of the apoptotic death pathway more easily conceivable. Becau...

Validation of Growth Differentiation Factor (GDF-15) as a Radiation Response Gene and Radiosensitizing Target in Mammary Adenocarcinoma Model

“…Radiation-induced ceramide has been shown to promote membrane-associated receptor activation by facilitating the clustering of receptors within lipid rafts [Balaban et al, 1996, Goldkorn et al, 1997. The inducible alteration in gene expression is a fundamental molecular event of mammalian cells in response to ionizing radiation, and the fate of cells will at least partially depend upon the inducible changes in expression of some genes involved in these complex regulatory pathways resulting in cell cycle delays, cell killing or apoptosis and DNA repair [Chaudhry et al, 2003, Cucinotta et al, 2002Vallat et al, 2003. The cDNA microarray technology, allowing a large-scale expression profiling analysis, can provide tremendous information for elucidating the complex cellular response to radiation.…”

Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients

“…29 This also holds true for blk, a gene encoding an SRC (sarcoma virus) kinase found to be downregulated in B-cell chronic lymphocytic leukemia cells that were resistant to DNA damageinduced apoptosis. 30 Of importance, in Ph chromosomepositive leukemia a role of tyrosine kinases has been stated for reducing BCR-ABL dependence and for reducing imatinib efficacy. 13 In addition, it has been suggested that downregulation of tumor necrosis factor receptor-associated protein 1 (TRAP1), a member of the heat-shock family of proteins, might play an important role in the induction of apoptosis potentially caused by the formation of reactive oxygen species (ROS).…”

Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies

“…Furthermore, c-IAP1 was identified by gene expression profiling as one of the genes that was upregulated in CLL cells, which were resistant to DNA damage-induced apoptosis, compared with sensitive samples. 58 By comparison, immunocytochemical analysis of c-IAP1, c-IAP2 and XIAP expression in CLL patients revealed no correlation between expression levels of IAP proteins and sensitivity to fludarabine-induced apoptosis or prognostic factors, 59 indicating that IAP protein expression was not generally linked to defective DNA-damage response. Moreover, gene expression profiling of the IAP genes in hematological malignancies unraveled a specific pattern of expression of c-IAP1, c-IAP2 and survivin in CLL, B-cell ALL and follicular lymphoma samples that discriminated these diseases from each other and from other entities.…”